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Short Convergent Synthesis of the Mycolactone Core 
Through Lithiation-Borylation Homologations 
Christopher A. Brown[a] and Varinder K. Aggarwal*[a] 
Abstract: Using iterative lithiation-borylation homologations, the 
mycolactone toxin core has been synthesised in 13 steps and 17% 
overall yield. The rapid build-up of molecular complexity, high 
convergence and high stereoselectivity are noteworthy features of the 
synthesis. 
The third most common Mycobacterium infection (after M. 
tuberculosis and M. leprae) is that of M. ulcerans, the pathogen 
responsible for the severe ulcerative skin disease, Buruli ulcer. [1] 
Endemic in tropical Africa, it infects over 5000 patients per annum 
with 48% of cases being aged under 15.[1a,2] Transmission is 
thought to occur by an aquatic organism bite,[3] with initial 
manifestation occurring as a painless skin nodule. If diagnosed 
early, simple antibiotic chemotherapy is effective (80%),[4] 
however if untreated, propagation of the infection results in large 
skin lesions of necrotic tissue and bone loss which are only 
treatable through aggressive surgery, resulting in scarring and 
loss of limb function.[2,5] The serious morbidity due to the socio-
economic burden of a young disabled workforce in rural 
communities[6,7] resulted in the World Health Organization 
identifying Buruli ulcer as one of seventeen neglected tropical 
diseases requiring research.[7] 
M. ulcerans secretes a unique polyketide-derived virulence 
factor, an equilibrating mixture of mycolactones A and B, 1 
(Scheme 1, 3:2 trans:cis) which inhibits the immune response and 
causes necrosis of the infected tissue.[1a,1c] Small and co-
workers[8] successfully isolated milligram quantities of 1 allowing 
structure elucidation by NMR[9] and confirmation of mycolactones 
A/B as the causative toxin through studies in vivo.[10] A number of 
congers (C-F) have since been isolated containing the common 
lactone 2, varying only by the appended acyl side chain.[11]  
Scheme 1. Structure of Mycolactone A/B 1 and Core 2 
The absolute stereochemistry of firstly the lactone core 2[12] 
and then mycolactones A/B 1[13] was determined through total 
synthesis by Kishi and co-workers. Multiple synthetic studies have 
since followed including a 3rd generation (>700mg)[14] synthesis 
of core 2 by Kishi, in addition to other accomplished syntheses by 
the groups of Negishi,[15] Blanchard,[16] and Altmann.[17] These 
efforts have enabled further research into the pathogenesis of 
Buruli ulcer,[18] aid the invention of new/simpler diagnostic 
techniques[19] and allowed structural activity relationships of the 
core.[16,17,20] These SAR investigations have shown that while the 
northern fragment can be augmented, a complete side chain is 
critical for the potency of 1.[20a] The side chain of 1 has already 
been synthesized by the groups of Kishi,[21] Negishi[22] and 
Feringa/Minnaard,[23] so we therefore focused our efforts towards 
the synthesis of the lactone core 2. We were particularly keen on 
applying our recently developed lithiation-borylation 
methodology,[24] which is highly effective in not only controlling 
stereochemistry but also simultaneously creating C-C bonds. 
Whilst such methodology has already been applied to a number 
of targets,[25] including strategies involving iterative 
homologations for generating contiguous stereocenters,[26] 
mycolactone core 2 represents a considerably higher level of 
complexity. Herein we describe our success in applying our 
lithiation-borylation methodology to a short convergent synthesis 
of this target molecule. 
Scheme 2. Retrosynthetic analysis of mycolactone core 2. PG = Protecting 
Group, pin = pinacolato, Cb = N,N-diisopropylcarbamoyl, sp = sparteine 
Our retrosynthetic analysis began with disconnection to the 
known intermediate 3 (Scheme 2).[12,15] We considered a 
lithiation-borylation disconnection between C11-C12 as this 
would lead to high convergency. Both boronic ester 4 and 
carbamate 5 could themselves be obtained through consecutive 
[a] C. A. Brown, Prof. Dr. V. K. Aggarwal 
School of Chemistry, University of Bristol 
Cantock’s Close 
Bristol, BS8 1TS (United Kingdom) 
E-mail: V.Aggarwal@bristol.ac.uk 
[**] We thank EPSRC (EP/I038071/1) and the European Research 
Council (FP7/2007-2013, ERC grant no. 246785) for financial 
support. We thank Dr. Eddie Myers and Dr. Daniele Leonori for 
helpful suggestions. 
 Supporting information for this article is given via a link at the end of 
the document. 





lithiation-borylation reactions of fragments 7 and 10. Indeed, 
through our iterative methodology there was the prospect of 
coupling boronic ester 7 with building block 6 followed by 
carbamate 5 in one pot to give the lactone precursor 3. Similarly 
carbamate 5 could be constructed in one pot from iterative 
coupling of boronic ester 10 and carbamates 9 and 6. 
We began with the synthesis of boronic ester 10, which was 
achieved in three high yielding steps (Scheme 3). Copper-
catalyzed formal hydroboration[27] of alkynol 11 with B2pin2 in the 
presence of MeOH gave the desired vinyl boronate in 83% yield 
as a single regio- and stereoisomer. Subsequent carbamoylation 
of the alcohol gave carbamate 12 in 87% yield. Matteson one-
carbon homologation with chloromethyllithium 13 (formed in situ 
with 12)[28] gave the desired allylic boronic ester 10 as a 99:1 
mixture with 12. High conversion was achieved through the 
addition of precooled nBuLi[29] and using an excess of the dihalide 
with respect to the organolithium to limit competing addition of 
nBuLi to boronic ester 12 and thereby favour lithium-halogen 
exchange. In contrast to vinyl boronic ester 12, allylic boronic 
ester 10 was unstable to silica gel but was nevertheless obtained 
in high purity by simple filtration and evaporation. 
Scheme 3. Synthesis of 10. a) CuCl (5 mol%), PPh3 (6 mol%), KOtBu (20 
mol%), B2pin2, MeOH, THF, 83%; b) CbCl, Et3N, THF, 87%; c) BrCH2I or ClCH2I 
(3.5 equiv.), nBuLi (2.4 equiv.), Et2O (0.4 M), −78 °C or −95 °C, 99% 
With boronic ester 10 in hand, our key lithiation-borylation 
reactions were examined (Scheme 4). The boronate complex, 
formed from the addition of 10 into 6 (1.5 equiv.), underwent 1,2-
metallate rearrangement in refluxing Et2O to form 14 in 83% yield. 
NMR analysis of the derived Mosher’s ester showed that the 
homologation occurred in 97:3 er. Subsequent reaction of 14 with 
9 (1.3 equiv.) proceeded well, providing alcohol 15 after oxidation 
in 77%, >97:3 er and 94:6 dr. The diastereomeric ratio is 
consistent with reactions that are under full reagent control 
employing lithiated carbamates 6 and 9 with 97:3 er. Thus, 
carbamate 15 was formed in 63% yield from 12 in three steps. 
These three steps could also be carried out sequentially, without 
intermediate purification (‘one-pot‘), on identical scale in an 
increased 81% yield without detriment to dr and further performed 
on an 8 mmol scale thereby delivering 3.0 g of 15, with 85% 
recovery of (+)-sparteine. The potentially reactive carbamate 
group remained intact allowing us to circumvent functional group 
manipulation and, after C5 silyl protection (82%), we obtained the 
desired carbamate 5 in 48% over 6 steps from alcohol 11. 
The synthesis of boronic ester 4 started with preparation of 7 
g of alkene 8 through a four-step known procedure in 74% yield 
and 96:4 dr (Scheme 5).[15,17a] Direct formation of allylic boronate 
7 was investigated, employing methallyl boronic ester 17 and 
Hoveyda-Grubbs 2nd generation catalyst 19, which gave 7 in 62% 
yield but only as a 90:10 E:Z mixture of isomers. Olefin metathesis 
with vinylic boronic ester 18 has been reported to occur with much 
higher selectivity[30] and was therefore explored. We were pleased 
to find that subjecting alkene 8 and vinylic boronic ester 18 to the 
identical cross metathesis conditions, yielded 20 as a single 
geometric isomer (0.4 mmol scale, 68 % yield). However, upon 
scale up we encountered two major problems: i) a dramatic 
reduction in conversion (10% after 14 h, 3.8 mmol scale), and; ii) 
the formation of 1,2-disubstituted alkene 21 (15%). The latter 
observation has been described previously,[30] possibly due to the 
transposition of boron from the internal to the terminal position of 
alkene 18 and subsequent metathesis with 8. As this product was 
only observed by GC-MS after extended reaction times (over 10 
h), it was attributed to a transmuted catalyst of 19 causing the 
isomerisation of 18.[31] Therefore, it was imperative to increase 
conversion over a short reaction time to avoid catalyst 
degradation. Through running the reaction at higher concentration 
(1.0 M) and adding the catalyst portion-wise (5+5 mol%), we 
increased conversion to 45% and reduced the amount of 21 
formed (5%). Finally, periodic degassing of the reaction every two 
hours removed the ethylene content of the solution and further 
pushed the equilibrium towards vinyl boronate 20, achieving a 
60% yield on a 5.3 mmol scale over 10 hours with minimal 
formation of alkene 21 (<5%). 
 
 Scheme 5. Olefin Metathesis of 8 
With our two key building blocks in hand, we examined our 
final iterative lithiation-borylation process. Matteson one-carbon 
homologation of 20 proceeded in near quantitative yield and 
homologation of 7 with lithiated carbamate 6 (1.5 equiv.) gave our 
required fragment 4 in 81% isolated yield. Oxidation and NMR 
analysis showed it to be 97:3 dr, consistent with the homologation 
of 6 with analogous allylic boronate 10. For the final step, lithiation 
of 5 in the presence of (-)-sparteine was required, but in 
explorative lithiation-deuteration experiments we isolated diene 
22[32] in 10% yield, in addition to the required deuterated product 
(90%). This showed that 10% lithiation of 5 occurred at the allylic 
position followed by E2 elimination of the carbamate. We therefore 
used an excess of carbamate 5 (1.5 equiv.) with respect to 
boronic ester 4 (1.0 equiv.), and the final homologation and 
subsequent oxidation gave known intermediate 3 in 82% yield and 
high dr[33] with 950 mg prepared. With isolation and 
chromatographic purification of each intermediate, 3 was formed 
from 20 in 66% over three steps. Once again, these three steps 
could also be carried out sequentially, without intermediate 
purification (‘one-pot‘), in an increased 86% yield.  As a result,  






Scheme 4. 1CH = ClCH2I (3.5 equiv.), nBuLi (2.4 equiv.), Et2O (0.4 M), −95 °C, Formation of Carbenoids = Carbamate (1.0 equiv.), sparteine (1.0 equiv.), sBuLi 
(1.0 equiv.), Et2O (0.4 M), −78 °C, 5 h, Li-B = Carbenoid (1.5 equiv.), then RBpin (1.0 equiv.), −78 °C, 2 h, then 40 °C, 16 h, [O] = NaOH/H2O2, THF, 0 °C, 2 h, P = 
TBSCl (1.4 equiv.), imidazole (1.6 equiv.), DMF, 25 °C, 16 h
significant amounts (>900 mg) of 3 was obtained over 8 steps 
from (R)-3-hydroxybutyrate in 38 % overall yield. 
Completion of the synthesis followed literature precedent 
(Scheme 6).[12,15] Selective deprotection of the primary silyl ether 
with TBAF (85%), followed by a two-step TEMPO/Pinnick 
oxidation, yielded acid 23 in 81%. Lactonisation of the 12-
membered core proceeded efficiently under Yamaguchi 
conditions (81% yield), and subsequent global deprotection with 
HF·pyridine gave the mycolactone core 2 in 80%. In forming the 
lactone ring, minor diastereomers observed in the formation of 3 
were separated completing the synthesis of lactone 2, which was 
identical in all respects to the literature, in a total of 13 steps and 
17% overall yield. 
 
Scheme 6. Completion of synthesis. a) TBAF, THF, 85%; b) i. TEMPO (15 
mol%), BAIB, CH2Cl2/H2O (2:1); then b) ii. NaClO2, 2-methyl-2-butene, 
Na2H2PO4 buffer:tBuOH (2:1), 81%; c) (C6H2Cl3)COCl, DMAP, PhH, 81%; d) 
HF·pyridine, THF, 80% 
In conclusion, the shortest synthesis of the mycolactone core 
to date has been completed both in terms of longest linear 
sequence (13 vs 14[14] steps) and total step count (17 vs 28[14] 
steps).  Moreover if the sequenced iterative homologation is 
counted as one step, then the mycolactone core is achieved in 
only 10 steps. Although a scalable route has already been 
accomplished, our synthesis is able to rapidly deliver significant 
amounts (>100 mg) of highly enantio- and diastereoenriched 
mycolactone core through utilization of simple carbamate building 
blocks. Both in terms of step count and scale, the synthesis 
showcases the power of lithiation-borylation methodology for the 
efficient, and convergent synthesis of complex molecules. 
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Using iterative lithiation-borylation homologations, the mycolactone toxin core has 
been synthesised in 13 steps and 17% overall yield. The rapid build-up of molecular 
complexity, high convergence and high stereoselectivity are noteworthy features of 
the synthesis. See Scheme; TBS = tert-butylsilyl, pin = pinacolato, Cb = N,N-
diisopropylcarbamoyl, sp = sparteine 
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